Endocrine/Metabolic Rhythm Pharmaceuticals advances next-generation MC4R agonist toward clinic for hypothalamic obesity Dec. 7, 2023 Rhythm Pharmaceuticals Inc. has presented preclinical data on its new drug candidate, RM-718, a next-generation melanocortin MC4 receptor (MC4R) agonist for weekly administration with a potential development path for hypothalamic obesity.Read More